elidel and Aprepitant Interactions

Interactions between elidel(pimecrolimus topical) and Aprepitant (aprepitant)

pimecrolimus topical and aprepitant (Minor Drug-Drug)

Theoretically, coadministration with CYP450 3A inhibitors may increase the plasma concentrations of pimecrolimus, which has been shown in vitro to undergo metabolism by this subfamily of hepatic microsomal enzymes. Although clinically significant drug interactions are not expected due to minimal systemic absorption of topically administered pimecrolimus, the possibility cannot be ruled out. The manufacturer recommends caution in patients with widespread and/or erythrodermic disease.